The benefits and harms of intravenous thrombolysis with recombinant tissue plasminogen activator within 6 h of acute ischaemic stroke (the third international stroke trial [IST-3]): a randomised controlled trialStephen Phillips, Joanna M. Wardlaw, Gordon Murray et al.|The Lancet|2012Cited by 1.2k